Details for Patent: 8,236,804
✉ Email this page to a colleague
Title: | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Abstract: | The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine- , crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation. |
Inventor(s): | Bathe; Andreas (Darmstadt, DE), Helfert; Bernd (Ober-Ramstadt, DE), Neuenfeld; Steffen (Messel, DE), Kniel; Heike (Heppenheim, DE), Bartels; Matthias (Darmstadt, DE), Rudolph; Susanne (Dieburg, DE), Bottcher; Henning (Darmstadt, DE) |
Assignee: | Merck Patentgesellschaft (Darmstadt, DE) |
Filing Date: | May 04, 2011 |
Application Number: | 13/100,948 |
Claims: | 1. A method of treating a major depressive disorder, the method comprising: administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of a compound which is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride anhydrate in crystalline modification IV (Form IV) having at least five characteristic peaks selected from the degrees two-theta values corresponding to 9.08.+-.0.1, 12.85.+-.0.1, 14.50.+-.0.1, 16.89.+-.0.1, 18.89.+-.0.1, 20.43.+-.0.1, 21.72.+-.0.1, 24.61.+-.0.1, 27.35.+-.0.1 and 28.18.+-.0.1 and one or more conventional auxiliary substances and/or carriers, wherein the major depressive disorder is treated in the patient. 2. The method of claim 1, wherein the compound has at least five characteristic peaks selected from the degrees two-theta values corresponding to 12.85.+-.0.1, 14.50.+-.0.1, 20.43.+-.0.1, 21.72.+-.0.1, 27.35.+-.0.1 and 28.18.+-.0.1. 3. The method of claim 1, wherein the compound has characteristic peaks at the degrees two-theta values corresponding to 9.08.+-.0.1, 14.50.+-.0.1, 18.89.+-.0.1, 20.43.+-.0.1 and 24.61.+-.0.1. 4. The method of claim 1, wherein, the compound has a solubility in water of about 0.33 .mu.g/mL. |